Parnax Lab Limited share price
Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic; herbal; and nutraceutical products. It also provides oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services. The company was formerly known as K…Read more
- Market Cap—
- Current Price₹ 112.92
- High / Low₹ 150 / 104
- Stock P/E14.5
- Book Value₹ 83
- Dividend Yield0.00 %
- ROCE16.3 %
- ROE13.20 %
- Face Value—
More figures (10)
- EPS (TTM)₹ 7.79
- Price / Book1.36
- OPM9.5 %
- Debt / Equity0.87
- Sales growth (4Y)14.0 %
- Profit growth (4Y)11.0 %
- Promoter holding85.3 %
- EV / EBITDA8.7
- Beta0.05
- All-time high₹ 150
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| PARNAXLAB | -6.10% | — | — | — | — | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Parnax Lab Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare).
- It trades at 14.5 times its last 12 months' earnings and 1.4 times book value.
- Revenue grew 14.0% a year over the last 4 years, profit 11.0% a year.
- Return on equity was 13.2% and return on capital employed 16.3% in the latest year.
- Debt was 0.87 times shareholders' equity.
- The share price is 24.5% below its 52-week high.
- Promoters and insiders hold about 85.3%; institutions about 0.0%.
Pros
AI- Healthy return on equity of 14.2% on average over the last 3 years.
Cons
AI- The company has not paid a dividend recently.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Parnax Lab Limited
Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic; herbal; and nutraceutical products. It also provides oral formulations, such as cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provides drug identification and development services; in- and out-licensing services; and contract research and manufacturing services. The company was formerly known as Krishna-Deep Trade & Investments Limited and changed its name to Parnax Lab Limited in April 2012. Parnax Lab Limited was incorporated in 1982 and is headquartered in Mumbai, India.
- Employees
- 12
- Head office
- Mumbai
Peer comparison
HealthcareDrug Manufacturers - Specialty & Generic
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Parnax Lab | 112.92 | 14.5 | — | 0.00 | 0 | -87.00 | 57 | 6.42 | 16.3 | 13.2 | 1.36 | 9.5 | 0.87 | 85.34 | 249 | 14.0 |
| 2. | Sun Pharmaceutical Industries | 1,758.80 | 34.9 | 4,21,995 | 0.91 | 2,895 | 34.65 | 15,184 | 18.48 | 17.9 | 14.7 | 5.05 | 23.4 | 0.06 | 55.61 | 58,220 | 10.4 |
| 3. | Divi's Laboratories | 9,144.50 | 83.0 | 2,42,758 | 0.33 | 902 | 36.25 | 3,080 | 19.15 | 19.0 | 16.2 | 14.48 | 28.4 | 0.00 | 52.00 | 10,476 | 11.0 |
| 4. | Torrent Pharmaceuticals | 4,558.90 | 72.8 | 1,73,406 | 0.83 | 566 | 3.28 | 4,921 | 54.85 | 9.1 | 27.1 | 18.39 | 25.0 | 1.79 | 63.18 | 13,980 | 13.3 |
| 5. | Zydus Lifesciences | 1,123.00 | 25.0 | 1,12,020 | 0.09 | 940 | -19.74 | 7,802 | 24.03 | 19.0 | 19.7 | 4.17 | 21.7 | 0.46 | 75.18 | 26,720 | 16.5 |
| 6. | Laurus Labs | 2,060.10 | 101.8 | 1,11,310 | 0.12 | 362 | 123.94 | 2,026 | 29.10 | 19.5 | 18.2 | 20.98 | 19.4 | 0.48 | 32.03 | 6,813 | 3.8 |
| 7. | Cipla | 1,325.10 | 31.8 | 1,07,051 | 0.98 | 789 | -35.42 | 7,077 | 7.26 | 14.9 | 11.8 | 3.11 | 17.5 | 0.02 | 31.13 | 27,712 | 7.2 |
| 8. | Dr. Reddy's Laboratories | 1,233.00 | 31.0 | 1,02,707 | 0.66 | 444 | -68.72 | 8,071 | -5.56 | 14.2 | 12.1 | 2.68 | 14.9 | 0.21 | 30.14 | 33,593 | 11.0 |
| 9. | Aurobindo Pharma | 1,666.90 | 26.0 | 95,910 | 0.00 | 1,033 | 14.29 | 9,106 | 8.65 | 13.5 | 9.9 | 2.56 | 15.6 | 0.21 | 54.79 | 33,385 | 10.7 |
| 10. | Mankind Pharma | 2,275.50 | 46.0 | 93,988 | 0.00 | 568 | 35.00 | 4,031 | 30.89 | 13.7 | 12.5 | 5.76 | 19.9 | 0.39 | 75.39 | 14,278 | 17.7 |
| Median: 41 Co. | 1,712.85 | 30.8 | 23,878 | 0.35 | 679 | 8.79 | 5,999 | 18.81 | 15.6 | 16.2 | 4.55 | 16.9 | 0.30 | 55.20 | 20,499 | 13.5 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
| ₹ Cr | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 53 | 63 | 63 | 70 | 57 |
| Operating Profit | 5 | 6 | 5 | 3 | 2 |
| Profit before tax | 4 | 5 | 3 | 3 | 1 |
| Net Profit | 3 | 4 | 3 | 2 | 0 |
| EPS in Rs | 2.85 | 3.15 | 2.37 | 1.90 | 0.37 |
Profit & Loss
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 168 | 189 | 188 | 249 | |
| Operating Profit | 17 | 17 | 20 | 24 | |
| Interest | 5 | 5 | 5 | 6 | |
| Depreciation | 7 | 7 | 7 | 8 | |
| Profit before tax | 12 | 12 | 16 | 16 | |
| Net Profit | 9 | 10 | 12 | 12 | |
| EPS in Rs | 7.79 | 8.37 | 10.05 | 10.27 |
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 11 |
| Reserves | 51 | 60 | 72 | 84 |
| 55 | 81 | 70 | 83 | |
| Long term borrowings | 12 | 21 | 18 | 22 |
| Short term borrowings | 39 | 50 | 43 | 53 |
| 28 | 38 | 37 | 50 | |
| Trade payables | 15 | 24 | 21 | 32 |
| Minority interest | 0 | 0 | 0 | 0 |
| Current liabilities | 63 | 83 | 74 | 96 |
| Total Liabilities | 145 | 190 | 190 | 228 |
| 83 | 112 | 120 | 133 | |
| Gross block | 114 | 148 | 160 | 179 |
| Accumulated depreciation | 31 | 37 | 40 | 46 |
| Goodwill & intangibles | 0 | 1 | 1 | 1 |
| CWIP | 6 | 23 | 32 | 19 |
| 56 | 56 | 38 | 76 | |
| Inventories | 22 | 30 | 26 | 36 |
| Trade receivables | 28 | 33 | 31 | 38 |
| Cash & equivalents | 1 | 0 | 1 | 0 |
| Current assets | 61 | 77 | 68 | 93 |
| Total Assets | 145 | 190 | 190 | 228 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 21 | 16 | 32 | 8 | |
| Profit for the year | 9 | 10 | 12 | 12 |
| Working capital changes | -0 | -5 | 7 | -19 |
| Direct taxes paid | -3 | -3 | -3 | -4 |
| -10 | -32 | -16 | -16 | |
| Fixed assets purchased | -11 | -32 | -19 | -35 |
| Fixed assets sold | 1 | 0 | 3 | 19 |
| Investments purchased | -0 | -1 | ||
| Investments sold | 0 | 0 | 0 | |
| -14 | 15 | -16 | 8 | |
| Proceeds from borrowings | 20 | 14 | ||
| Repayment of borrowings | -15 | -10 | ||
| Interest paid | -5 | -5 | -5 | -6 |
| Net Cash Flow | -3 | -1 | 0 | -0 |
| Free Cash Flow | 10 | -17 | 14 | -27 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 13.9% | 14.4% | 14.9% | 13.2% |
| ROCE | — | 20.9% | 16.2% | 18.1% | 16.3% |
| Operating margin | — | 10.0% | 8.8% | 10.5% | 9.5% |
| Net margin | — | 5.1% | 5.1% | 6.1% | 4.7% |
| Debt / equity | — | 0.88 | 1.13 | 0.84 | 0.87 |
| Current ratio | — | 0.97 | 0.92 | 0.92 | 0.97 |
| Debtor days | — | 61 | 63 | 60 | 56 |
| Inventory days | — | 68 | 82 | 75 | 73 |
| Days payable | — | 46 | 65 | 62 | 65 |
| Cash conversion cycle | — | 83 | 80 | 73 | 64 |
| Working capital days | — | -4 | -12 | -12 | -4 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
- Promoters & insiders 85.34%
- Institutions (FII, DII, funds) 0.00%
- Public & others 14.66%
Key dates
- Ex-dividend date
- 1 Jan 1970
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Questions about Parnax Lab Limited
What is the share price of Parnax Lab Limited today?
What is the market cap of Parnax Lab Limited?
What is the P/E ratio of Parnax Lab Limited?
Is Parnax Lab Limited a good investment?
How can I buy Parnax Lab Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.